Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
66.11(c) 65.31(c) 65(c) 63.93(c) 63.69 Last
351 615 265 301 193 223 198 253 250 188 Volume
+0.82% -1.21% -0.47% -1.65% -0.38% Change
More quotes
Financials
Sales 2021 521 M 632 M 632 M
Net income 2021 -235 M -285 M -285 M
Net cash position 2021 3 011 M 3 650 M 3 650 M
P/E ratio 2021 -18,9x
Yield 2021 -
Sales 2022 581 M 705 M 705 M
Net income 2022 -257 M -312 M -312 M
Net cash position 2022 2 630 M 3 189 M 3 189 M
P/E ratio 2022 -18,0x
Yield 2022 -
Capitalization 4 189 M 5 080 M 5 078 M
EV / Sales 2021 2,26x
EV / Sales 2022 2,68x
Nbr of Employees 1 328
Free-Float 73,8%
More Financials
Company
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales are distributed geographically as follows: Europe (1.2%) and North America (98.8%). 
More about the company
Ratings of Galapagos NV
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about GALAPAGOS NV
06/08GALAPAGOSá : increases share capital through subscription right exercises (Form ..
PU
06/07Galapagos increases share capital through subscription right exercises
GL
06/04GALAPAGOSá : SELECTION study on filgotinib in ulcerative colitis published in Th..
PU
06/04GALAPAGOSá : Anti-inflammatory Drug Jyseleca Sustains Efficacy in Maintenance St..
MT
05/28GALAPAGOSá : to present data on rheumatoid arthritis at the upcoming European Le..
PU
05/19GALAPAGOSá : announces first patient enrolled in FILOSOPHY study to advance unde..
PU
05/19GALAPAGOSá : Enrolls First Patient in Post-Approval Study of Arthritis Drug
MT
05/18GALAPAGOSá : Launches Phase 4 Study of Filgotinib Rheumatoid Arthritis Medicatio..
MT
05/18Galapagos announces first patient enrolled in FILOSOPHY study to advance unde..
GL
05/10GALAPAGOSá : refocuses pipeline and rightsizes operations (Form 6-K)
PU
05/06GALAPAGOS NVá : 1st quarter earnings
CO
05/04GALAPAGOSá : Transparency notification received from The Capital Group
AQ
05/04GALAPAGOS NVá : Crossing thresholds
CO
05/03GALAPAGOSá : creates new subscription right plans
PU
04/28GALAPAGOSá : Written questions and answers
PU
More news
News in other languages on GALAPAGOS NV
06/07Galapagos verhoogt kapitaal door uitoefening inschrijvingsrechten
06/04Galapagos publiceert onderzoeksdata over filgotinib
06/04SELECTION-studie naar filgotinib bij colitis ulcerosa, gepubliceerd in The La..
05/27Galapagos presenteert nieuwe gegevens filgotinib tijdens reumacongres
05/27Galapagos presenteert tijdens het congres van de European League Against Rheu..
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 76,21 €
Last Close Price 63,93 €
Spread / Highest target 72,1%
Spread / Average Target 19,2%
Spread / Lowest Target -10,8%
EPS Revisions
Managers and Directors
NameTitle
Onno van de Stolpe Chief Executive Officer
Bart Filius President & Chief Operating Officer
Raj B. Parekh Chairman
Piet Wigerinck Chief Scientific Officer
Walid Abi-Saab Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
GALAPAGOS NV-20.56%5 080
MODERNA, INC.92.96%80 944
LONZA GROUP AG16.07%54 601
IQVIA HOLDINGS INC.37.73%47 315
CELLTRION, INC.-23.40%33 588
SEAGEN INC.-12.48%27 797